Lincoln Pharmaceuticals Ltd reports 23% rise in the Standalone Net Profit at Rs.14.99 crore in Q1FY21 Kumar Jeetendra | August 20, 2020 August 20, 2020: Lincoln Pharmaceuticals Limited, one of India’s leading healthcare companies has reported net profit of Rs. 14.99 crore for the Q1FY21 Ended June 2020 as against net profit of Rs. 12.16 crore in the corresponding period last year, growth of 23.2%. Net revenue for the quarter ended June 2020 reported at Rs. 103.01 …
Cipla and Stempeutics collaborate for launch of Stempeucel®, first ‘Made in India’ Cell Therapy to treat Critical Limb Ischemia (CLI) Kumar Jeetendra | August 20, 2020 India, Mumbai, August 20th , 2020: Cipla Limited (BSE: 500087; NSE: CIPLA EQ) referred to as “Cipla” today announced that its partner Stempeutics Research Pvt. Ltd has received regulatory approval by the Drug Controller General of India (DCGI) for the launch of Stempeucel® in India. The product is indicated for the treatment of CLI due …
Oxford-AstraZeneca antibody might be the main shot accessible for Indians Kumar Jeetendra | August 19, 2020 Amid the COVID-19 pandemic, India appears for Oxford-AstraZeneca vaccine candidate are the likely first shot available for Indians at the end of 2020. Additionally, there are two indigenously developed vaccine candidates, that are likewise being anticipated to have started with a gap few weeks if removed in trials, said a report from The Times of …
Dr Reddy’s dispatches Avigan (Favipiravir) tablets in India Kumar Jeetendra | August 19, 2020 Dr Reddy’s Laboratories on August 19 announced the launch of Avigan (Favipiravir) pills, used for treating mild to moderate COVID-19 sufferers in India. Dr Reddy’s stated Avigan was approved by the Drugs Controller General of India (DCGI) for treating patients with moderate to medium COVID-19. “The need for high efficacy and quality, affordability and improved …
Vaccine firm Biological E gains Akorn’s injectable plant in India for $10 million Kumar Jeetendra | August 17, 2020 Vaccine maker Biological E (BE), on August 17 stated it has acquired Akorn India, a subsidiary of US-based Akorn which generates speciality generic injectable medicines and vaccines for around $10 million in money. BE said the acquisition will allow the Hyderabad-based organization to boost its manufacturing capabilities and abilities to produce and furnish its vaccines …
In procedure of acquiring natural freedom for new plant in Madhya Pradesh: Ipca Labs Kumar Jeetendra | August 16, 2020 New Delhi, Aug 16 (PTI) Medicine manufacturer Ipca Laboratories is in the process of getting environmental clearance for a new production plant in Dewas, Madhya Pradesh, according to its 2019-20 annual report. Sharing information with the firm”s shareholders, the drug maker said the company has already acquired land to the job. “The organization is in …
Aurobindo Pharma expects stage I, II preliminaries by end of 2020 Kumar Jeetendra | August 14, 2020 Aurobindo Pharma has said it is expecting its suggested vaccine candidate for COVID-19 to undergo Phase I and II trials by the end of 2020, while Stage III might be performed during March-April next year.Managing Director of Aurobindo Pharma, Narayanan Govindarajan in the newly held earnings call with analysts said the city-based pharma major has …
Swiss Parenterals Limited received European Union (EU) GMP approval Kumar Jeetendra | August 8, 2020 India’s leading manufacturer of Sterile Injectables company to soon enter the EU markets with various range of injectables and expand gradually. Swiss Parenterals Limited, one of the India’s leading sterile injectable manufacturer has received the European Union (EU) GMP for its two state of the art manufacturing facilities located at Bavla in Gujarat. The certification …
New test can pinpoint which individuals with gonorrhea can be relieved with ciprofloxacin Kumar Jeetendra | August 7, 2020 A test made by UCLA researchers could pinpoint which individuals with gonorrhea will react successfully to the inexpensive oral antibiotic ciprofloxacin, which had formerly been sidelined over concerns the bacterium that causes the disease was becoming resistant to it. In study published in the peer-reviewed journal Clinical Infectious Diseases, a UCLA-led team found that of …
Pfizer signs deal to produce and flexibly Gilead’s remdesivir for COVID-19 treatment Kumar Jeetendra | August 7, 2020 The US drugmaker would provide contract manufacturing services in its facility in Kansas to create the medication. Pfizer Inc said on Friday it signed up a multi-year agreement with Gilead Sciences Inc to manufacture and provide the organization’s antiviral drug remdesivir for COVID-19 patients. The US drugmaker would provide contract manufacturing services at its center …
BDR Pharmaceuticals dispatches Favipiravir at Rs 63 for each tablet in India Kumar Jeetendra | August 5, 2020 Drug firm BDR Pharmaceuticals on Wednesday said it has established its antifungal medication Favipiravir for treating COVID-19 patients in India at a cost of Rs 63 each tablet. The business has also come up with a patient assistance programme which will allow patients and institutions who have limited resources to buy the medicine at an …
Working together with govt organizations to create treatment for COVID-19: Cipla Kumar Jeetendra | August 5, 2020 Medication major Cipla is working together with government agencies to come up with a treatment for COVID-19 while ramping up the production of various life saving essential drugs, according to company’s chairman YK Hamied. Sharing information with business’s shareholders at the drug firm’s annual report for 2019-20, Hamied said the company is at the forefront …
